To examine the clinical response of ZFP36/TTP to treatment with enzalutamide (a nonsteroidal anti-androgen therapy), we examined 2 clinical cohorts where the prostate tumors from the same patient were investigated before and after enzalutamide treatment. The gene discussed is ZFP36; the disease is prostate neoplasm.